About Curie Capital
Curie Capital is a venture capital firm founded in 2018. It is primarily based out of Amsterdam, Netherlands. As of Dec 2025, Curie Capital is an active investor, having invested in 7 companies, with 1 new investment in the last 12 months. It primarily invests in Series A round in Netherlands based startups. Its investments are spread across Life Sciences and Healthcare sectors. Most recently it participated in the $***** Series A round of TargED A lot of funds co-invest with Curie Capital, with names like BOM sharing a substantial percentage of its portfolio. Curie Capital has team of 8 people including 3 partners.Key Metrics
Team Members
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Seed & Series A
Portfolio Soonicorns
Curie Capital's List of Top Investments
Curie Capital has a portfolio of 7 companies. Their most notable investments are in Citryll and Allero Therapeutics.Their portfolio spans across and Netherlands. They have invested in Life Sciences, Healthcare, across Seed, Series A stages. Here is the list of top investments by Curie Capital:1. Citryll
Citryll is a US-based biopharma developing antibody therapeutics to target neutrophil extracellular traps for autoimmune diseases like Rheumatoid Arthritis (RA), Colitis and others. The therapeutics work by extinguishing the source of auto-antigens and neutrophil extracellular trap (NET) derived toxic molecules instead of broadly targeting inflammation. The company is a spin-out from ModiQuest. Citryll has a proprietary toolbox to study NET biology and protein citrullination and their role in human pathologies. Citryll’s lead programme tACPA, targets the formation of neutrophil extracellular traps, called NETs. These drugs work by interfering with the formation, function, and clearance of NETs downstream of the protein citrullination pathway catalyzed by peptidyl-arginine deiminase (PAD) enzymes.
Key facts about Citryll
- Founded Year: 2015
- Location: Amsterdam (Netherlands)
- Stage: Series B
- Total Funding till date: $128M
- Employee Count: 18 as on Jul 01, 2024
- Investors: Forbion, BioGeneration Ventures and 11 Others
- Latest Funding Round: Series B, Dec 09, 2024, $*****
- Highlight: Editors' Pick
2. TargED
Developer of biological drugs for the treatment of thrombosis. The company offers its FDA-approved biological drugs and TargED Targeted Enzyme Delivery system which is a small antibody that can target the specific sites of thrombosis and enable the blood flow to reduce the risk for organ failure is reduced. The company target Thrombotic thrombocytopenic purpura (TTP) and Acute Ischemic Stroke (AIS) and the lead compound Microlyse is a thrombolytic fusion protein that consisting two subunits i.e a nanobody domain targeting Von Willebrand Factor (VWF) which helps in wound healing also and the protease domain of the plasminogen activator urokinase. It targets the protease domain towards VWF, to active degradation of both VWF and fibrin.
Key facts about TargED
- Founded Year: 2020
- Location: Utrecht (Netherlands)
- Stage: Series A
- Total Funding till date: $82.8M
- Employee Count: 10 as on Jul 01, 2024
- Investors: Inkef, Hadean Ventures and 8 Others
- Latest Funding Round: Series A, Dec 18, 2025, $*****
- Highlight: Editors' Pick
Key facts about Sirius Medical
- Founded Year: 2017
- Location: Eindhoven (Netherlands)
- Stage: Series B
- Total Funding till date: $28.2M
- Employee Count: 25 as on Jul 01, 2024
- Investors: Invest-NL, Norgine Ventures and 8 Others
- Latest Funding Round: Series B, Feb 04, 2025, $*****
4. Avidicure
Developer of immunotherapies for cancer therapeutics. It offers AVC-Boosters supercharged antibodies that boost the number and function of NK cells at the tumor, cause activation of the full immune system and provide broad TME-resistant anti-tumor responses.
Key facts about Avidicure
- Founded Year: 2022
- Location: Amsterdam (Netherlands)
- Stage: Seed
- Total Funding till date: $50M
- Investors: EQT, Kurma Partners and 4 Others
- Latest Funding Round: Seed, Apr 24, 2025, $*****
_1547095140316.png?format=webp&height=120&width=120){kind=logo}
5. Cleara
Developer of biomarkers and therapies to treat cancer and aging diseases. The company has discovered a protein biomarker, FOXO4 targeting FOXO4 proteins (neutralizing Doxorubicin-induced chemotoxicity) to inhibit and induce apoptosis in senescent cells via P53 genes.
Key facts about Cleara
- Founded Year: 2017
- Location: Utrecht (Netherlands)
- Stage: Seed
- Total Funding till date: $2.5M
- Employee Count: 9 as on Jul 01, 2024
- Investors: TruVenturo, TA Ventures and 5 Others
- Latest Funding Round: Seed, Sep 28, 2022, $*****
Curie Capital's Year-on-Year Investment Trends
Curie Capital has invested in 7 companies over the last 7 years, with an average of 1 new investment annually in the last 5 years. In 2025, it made 3 investments. Its most recent first time investment was in Avidicure and most recent follow-on round was in TargED.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 0 | 0 |
2025 | 1 | 2 | 3 |
2024 | 1 | 0 | 1 |
2023 | 0 | 1 | 1 |
2022 | 1 | 1 | 2 |
2021 | 0 | 1 | 1 |
2020 | 2 | 0 | 2 |
2019 | 2 | 0 | 2 |
Curie Capital's Investments by Stage
Curie Capital has made 4 investments in Seed stage with an average round size of $18M and 3 investments in Series A stage with an average round size of $14.4M.Stage of entry | No. of Investments |
|---|---|
Seed | 4 |
Series A | 3 |
Note: We have considered here, only first round of investments
Curie Capital's Investments by Sector
Curie Capital has a diverse portfolio, with companies operating in the Life Sciences and Healthcare. Notably, it has invested in 6 Tech companies, 5 Enterprise (B2B) companies and 1 Software company.Sector | No. of Investments |
|---|---|
Life Sciences | 6 |
Healthcare | 1 |
Note: We have considered here, only first round of investments
Curie Capital's Investments by Geography
Curie Capital has made most investments in Netherlands (7).Curie Capital's recent investments
Curie Capital has not made any investment in 2026 so far.Here are the most recent investments by Curie Capital:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Dec 18, 2025 | Netherlands | Series A | 3602 | ||
Apr 24, 2025 | Netherlands | Seed | 5045 | [+4] | |
Feb 04, 2025 | Netherlands | Series B | 1343 | [+4] | |
Apr 24, 2024 | Netherlands | Series A | 7396 | [+4] | |
Apr 12, 2023 | Netherlands | Series B | 9541 | [+3] |
Team profile of Curie Capital
Curie Capital has a team of 8 members including 3 Partners located in Netherlands. Curie Capital's team does not sit on the board of any company as of now.Here is a list of all team members in Curie Capital:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Amsterdam | - | ||
Partner | Amstelveen | - | ||
Partner | Amsterdam | - |
Co-investors of Curie Capital
Over the past 7 years, 43 investors have co-invested in Curie Capital's portfolio companies. This includes only funds.
- Invested before Curie Capital: FJ Labs, Swanbridge Capital and 3 others have invested in rounds before Curie Capital. There is 1 company where FJ Labs has invested before Curie Capital and 1 company where Swanbridge Capital has invested before Curie Capital.
- Top Co-investors of Curie Capital: 18 investors entered a company along with Curie Capital. These include investors like BOM (3 companies).
- Invested after Curie Capital: A total of 20 investors have invested in Curie Capital's portfolio after their investments. Top Investors include BioGeneration Ventures (2 companies), Seventure Partners (1 company) and Brightgene (1 company).
Recent News related to Curie Capital
•
Laigo Bio Raises €11.5M in Seed FinancingFinSMEs•Dec 04, 2025•LAIGOBIO, Kurma Partners, Curie Capital, Argobio and 3 others
•
Avidicure Secures $50M in Seed Funding for Novel Cancer TherapyFinSMEs•Apr 24, 2025•Avidicure, V-Bio Ventures, Curie Capital, Bureau of Meteorology and 3 others
•
Eindhoven-based Sirius Medical Raises €10Million in Additional Scale-up FundingStartup Rise EU•Feb 05, 2025•Sirius Medical Supply, Inc., Holmium Technologies, Curie Capital, Holland Capital and 2 others
•
Sirius Medical Raises €10M in Additional FundingFinSMEs•Feb 05, 2025•Sirius Medical, Curie Capital, Holland Capital, and 2 others
•
On World Cancer Day, Eindhoven’s Sirius Medical announces securing €10M to advance breast cancer surgerySilicon Canals•Feb 04, 2025•Sirius Medical, Invest-NL, NextGen Recruitment Ventures, Holland Capital and 2 others
•
Dutch biotech nabs €85M to position inflammatory antibody for a pharma buyerEndPoints News•Dec 09, 2024•Citryll, Johnson & Johnson Innovation, Forbion, Novartis Venture Fund and 6 others
•
Citryll gains Series B funds to develop NET-targeting antibodyPharmaceutical Technology•Dec 09, 2024•Citryll, Novartis Venture Fund, Johnson & Johnson Innovation, Forbion and 5 others
•
Flindr Therapeutics: Precision Oncology Company Raises €20 MillionPulse 2.0•Apr 30, 2024•Flindr, BioVentures Investors, Qbic Fund, Johnson & Johnson Innovation and 4 others
•
Dutch-based Flindr Therapeutics secures €20M to discover and develop precision oncology therapeuticsSilicon Canals•Apr 25, 2024•Flindr, V-Bio Ventures, Johnson & Johnson Innovation, Qbic Fund and 4 others
•
Sirius Medical, which wants to improve the care process of cancer patients, received an investment of 12 million euros.egirisim•Mar 31, 2023•Sirius Medical, Holland Capital, BOM, Curie Capital and 2 others
